Carlos Alberto von Mühlen

Hospital Moinhos de Vento

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Luís Eduardo Coelho Andrade

Fleury S.A. (Brazil)

Wilson de Melo Cruvinel

Pontifícia Universidade Católica de Goiás

Paulo Luiz Carvalho Francescantônio

Pontifícia Universidade Católica de Goiás

Carlos David Araújo Bichara

Universidade Federal do Pará

Wilton Silva dos Santos

Universidade Federal de Santa Maria

Suzane Pretti Figueiredo Neves

Universidade Federal de Minas Gerais

Jozélia Rêgo

Universidade Federal de Goiás

Alessandra Dellavance

Fleury S.A. (Brazil)

Cristóvão Luís Pitangueira Mangueira

Hospital Israelita Albert Einstein

Darlene Gonçalves Carvalho

Hermes Arzneimittel (Germany)

Cooperative Institutions

Center for Rheumatology

Pontifícia Universidade Católica do Rio Grande do Sul

University of Zurich

Inserm

Istituti di Ricovero e Cura a Carattere Scientifico

Hospital São Lucas da PUCRS

Université Paris Cité

University of Milan

Universidade Federal do Rio Grande do Sul

Universidade de São Paulo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial

Arthritis & Rheumatism (2011)

William F. C. Rigby H-P Tony Kurt Oelke Bernard Combe Andrew J. Laster

To evaluate the efficacy and safety of treatment with ocrelizumab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and an inadequate response to MTX.STAGE was a phase III randomized, double-blind, parallel-group international study to evaluate the safety and efficacy of ocrelizumab compared with placebo in patients with active RA continuing MTX treatment. Patients receiving stable doses of MTX were randomized to receive 2 infusions of placebo (n = 320), ocrelizumab 200 mg (n = 343), or ocrelizumab 500 mg (n = 343) on days 1 and 15 as well as weeks 24 and 26. Coprimary end points were the proportion of patients with an American College of Rheumatology 20% improvement criteria (ACR20) response at weeks 24 and 48. Secondary end points included the change from baseline in the modified Sharp/van der Heijde score (SHS) and the ACR50/70 responses.The ACR20 response rates were 35.7% in the placebo group, 56.9% in the ocrelizumab 200 mg group, and 54.5% in the ocrelizumab 500 mg group at 24 weeks, and 27.6%, 58.3%, and 62.1%, respectively, at 48 weeks (P < 0.0001 versus placebo for each dose at both time points). At week 48, both of the ocrelizumab doses improved the ACR50 and ACR70 response rates 3-fold as compared with placebo and showed a statistically significant (P < 0.0001) reduction in joint damage progression relative to placebo (mean change in SHS reduced by 85% and 100% for the 200-mg and 500-mg doses, respectively). Rates of serious infection were comparable in the placebo (3.48 per 100 patient-years) and ocrelizumab 200 mg (3.54 per 100 patient-years) groups but were elevated in the ocrelizumab 500 mg group (8.66 per 100 patient-years).With both ocrelizumab doses, the primary end point was met, and the signs and symptoms of RA were significantly improved at weeks 24 and 48. Ocrelizumab also significantly inhibited the progression of joint damage. A higher rate of serious infections was observed with 500 mg of ocrelizumab as compared with ocrelizumab 200 mg or placebo.

Ocrelizumab

10.1002/art.33317

Cite

Citations (71)

Queixas musculoesqueléticas em músicos: prevalência e fatores de risco

Revista Brasileira de Reumatologia (2007)

Annemarie Frank Carlos Alberto von Mühlen

Disfunções musculoesqueléticas relacionadas à prática instrumental são freqüentes entre músicos, atingindo acima de 70% dos componentes de orquestras. O exercício da música como profissão requer ampla diferenciação e produtividade de capacidades tanto psicológicas, mentais, como também físicas. Muitos fatores de risco contribuem para o surgimento de queixas musculoesqueléticas durante a prática musical, entre eles: a técnica individual, as condições físicas do músico e o instrumento em si. Podem ocorrer distúrbios reumatológicos, neurológicos, dermatológicos e psicológicos, assim como problemas de visão e audição e do complexo orofacial. As queixas no aparelho motor manifestam-se, muitas vezes, como dor, fraqueza ou tensão. Os diagnósticos do membro superior mais freqüentemente estabelecidos são as tendinopatias, mialgias e a síndrome do superuso. O médico e o terapeuta responsáveis devem conhecer as atividades e cargas do músico profissional, para que sejam proporcionadas avaliação e estratégia terapêutica adequadas.

10.1590/s0482-50042007000300008

Cite

Citations (36)

The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative - Update and Its Impact

‏Edward K.L. Chan Jan Damoiseaux Gabriel Carballo Karsten Conrad Wilson de Melo Cruvinel

Source

Cite

Citations (0)

O teste do anti-HSP70 na investigação da etiologia auto-imune da Doença de Ménière

Bruna Fornari Vanni Michelle Lavinsky Wolff Humberto J. C. Bassanesi Cíntia D'Ávila Cristiano Ruschel

Source

Cite

Citations (0)

Paget’s Disease of Bone

Springer eBooks (2017)

Inês Guimarães da Silveira Melissa Cláudia Bisi Aline de Souza Streck Caroline Zechlinski Xavier de Freitas Deonilson Ghizoni Schmoeller

Osteitis Deformans

Bone tissue

10.1007/978-3-319-31169-2_33

Cite

Citations (0)

Lupoid sclerosis

Rheumatology International (2009)

Briele Keiserman Luiz Fernando Garcias da Silva Mauro Waldemar Keiserman Carlos Alberto von Mühlen Henrique Luiz Staub

Scleroderma (fungus)

10.1007/s00296-009-1175-1

Cite

Citations (12)

Fabricantes profissionais de cerâmica aln de alto desempenhoBrazilian Guidelines for autoantibodies on HEp-2 cells

Paulo Luiz Carvalho Francescantônio Wilson de Melo Cruvinel Alessandra Dellavance Luís Eduardo Coelho Andrade Ben Hur Taliberti

Cite

Citations (0)

Prateleiras para prateleiras móveis manuais para arquivos móveis Prateleiras arquivo compacto Biblioteca do EscritórioBrazilian Guidelines for autoantibodies on HEp-2 cells

Paulo Luiz Carvalho Francescantônio Wilson de Melo Cruvinel Alessandra Dellavance Luís Eduardo Coelho Andrade Ben Hur Taliberti

Cite

Citations (0)

Anticorpos contra LDL-ox e síndrome coronariana aguda

Arquivos Brasileiros de Cardiologia (2010)

Ana Maria Brito Medeiros Carlos Alberto von Mühlen Magnus Gidlund Rodrigo Bodanese Maria Gabriela Valle Gottlieb

The oxidation of low-density lipoprotein (oxLDL) induces the formation of immunogenic epitopes in molecules. The presence of autoantibodies against oxLDL has been demonstrated in the serum of patients with coronary artery disease (CAD). However, the role of these autoantibodies in the pathophysiology of acute coronary syndromes (ACS) and their clinical significance remain undefined.To evaluate the association between antibodies against oxLDL and ACS.Titers of IgG autoantibodies against oxLDL by copper (anti-oxLDL) and anti-D synthetic peptide derived from apolipoprotein B (antipeptD) were determined by Enzyme-linked immunosorbent assay (ELISA) in 90 patients, in the first 12 hours of ACS (cases) and in 90 patients with chronic CAD (controls).The results showed that the titers of anti-oxLDL were significantly higher (p = 0.017) in cases (0.40 +/- 0.22) than in controls (0.33 +/- 0.23). On the other hand, the titers of antipeptD were significantly lower (p < 0.01) in cases (0.28 +/- 0.23) than in controls (0.45 +/- 0.30). The difference in the titers of both antibodies between the two groups was independent of age, sex, hypertension, diabetes mellitus, dyslipidemia, body mass index, smoking, lipid profile, statin use and family history of CAD.The results showed that the titers of anti-oxLDL were significantly higher in patients with acute coronary syndrome as compared to patients with coronary artery disease and may be associated with atherosclerotic plaque instability.

10.1590/s0066-782x2010005000063

Cite

Citations (17)

International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins

Clinical and Vaccine Immunology (2006)

Michael Mähler Kai Kessenbrock Magdalena Szmyrka−Kaczmarek Yoshinari Takasaki Ignacio Garcı́a-De La Torre

ABSTRACT Autoantibodies to the ribosomal phosphoproteins (Rib-P) are a serological feature of patients with systemic lupus erythematosus (SLE). The reported prevalence of anti-Rib-P antibodies in SLE ranges from 10 to 40%, being higher in Asian patients. The variation in the observed frequency may be related to a number of factors but is dependent in large part on the test system used to detect the autoantibodies. An association of anti-Rib-P with central nervous system involvement and neuropsychiatric manifestations of SLE has been controversial. In the present international multicenter study, we evaluated the clinical accuracy of a new sensitive Rib-P-specific enzyme-linked immunosorbent assay based on recombinant Rib-P polypeptides. The results showed that 21.3% of 947 SLE patients, but only 0.7% of 1,113 control patients, had a positive test result ( P < 0.0001). The sensitivity, specificity, positive and negative predictive values, and diagnostic efficiency were determined to be 21.3%, 99.3%, 95.6%, 62.2%, and 65.3%, respectively. When evaluated in the context of participating centers, the prevalence of anti-Rib-P antibodies was found in descending frequency, as follows: China (35%) > Poland (34%) > Japan (28%) > United States (26%) > Germany (Freiburg; 23.3%) > Denmark (20.5%) > Germany (Berlin; 19%) > Mexico (15.7%) > Israel (11.7%) > Brazil (10%) > Canada (8%). The substantial data from this study indicate that the prevalence of anti-Rib-P antibodies may not be restricted to the genetic background of the patients or to the detection system but may depend on regional practice differences and patient selection. We confirm previously reported associations of antiribosomal antibodies with clinical symptoms and serological findings. Remarkably, we found a lower occurrence of serositis in Rib-P-positive lupus patients.

Ribosomal protein

10.1128/cvi.13.1.77-83.2006

Cite

Citations (94)